Bicara Therapeutics Inc.

NasdaqGM:BCAX Stock Report

Market Cap: US$993.1m

Bicara Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Bicara Therapeutics has a total shareholder equity of $509.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $524.2M and $14.6M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$520.76m
EquityUS$509.56m
Total liabilitiesUS$14.62m
Total assetsUS$524.17m

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: BCAX's short term assets ($521.5M) exceed its short term liabilities ($14.5M).

Long Term Liabilities: BCAX's short term assets ($521.5M) exceed its long term liabilities ($137.0K).


Debt to Equity History and Analysis

Debt Level: BCAX is debt free.

Reducing Debt: BCAX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BCAX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BCAX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 24.5% each year


Discover healthy companies